UK markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
635.16+1.16 (+0.18%)
At close: 04:00PM EST
634.00 -1.16 (-0.18%)
After hours: 07:23PM EST
Sign in to post a message.
  • R
    Rex
    Len said they are always developing new monoclonal antibodies regardless on new variants today on CNBC so I'm not too worried at this point not to mention things are way overblow with omicron at this point since there are no reported cases in the US although I'm sure there will be sooner than later. People will start bargain hunting once the dust settles and I'm sure Regn will be included in that basket.
  • G
    Greenbul
    According to EUA omicron hits both binding regions of the cocktail: N440K (28-fold) for imdevimab, Q493K (>438-fold) for casirivimab. There is no data about G446S, but G446V (which is not present in omicron) affects imdevimab 135 fold accoding to "In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans" article.
  • E
    Ed
    REGEN-COV may not be effective against all the mutations on the new variant. However, on the conference call Dr. Yancopoulos said the company was working on a next generation cocktail to respond to new variants. Wonder if they were able to anticipate the South African variant and design a cocktail that can neutralize it?
  • M
    Matt
    This name is constantly beat down whenever positive reopening news came out or vaccine development from the big names came out despite NOT being a Covid story (it’s icing on the cake of a severely undervalued business). Now, renewed Covid fears aren’t moving the stock up either. Go figure
  • J
    Juan
    Isn't news that regen-cov may not be effective against Omicron indirectly very good news? Regeneron excels in making new monoclonal antibodies quickly thru its veloimmune tech. That means new government contracts and new public demand.
  • J
    Juan
    Prem- i do not know what stat you want me to cite. Everything I wrote is easily confirmable Google - NU 500 times nu competitively.

    I don't do disinformation and I do not make money if there is a new breakout variant. I own 23 stocks. Most would be devastated by another pandemic at least in the short term
  • A
    AlanC
    Does anybody think that the investors conference will move this stock next week
  • J
    Juan
    Merck revised its antiviral's efficacy down to 30% for reduction in hospitalizations and deaths. This update is directly from Merck

    My guess is Paxlovid will also be less useful than advertised
  • d
    diep
    (http://trademarketview.tech) is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry. I don’t start trading without reading their daily email each morning!
  • R
    Rex
    Putting all the medical mumbo jumbo aside, who can explain the current pop? Sounds like there must be something positive about the cocktail helping out with the new variant. Anybody?
  • J
    Juan
    Regeneron entered into a partnership with Nykode Therapeutics to develop vaccines against cancer and infectious diseases. High end cost of collab could be close to 1 billion dollars for Regeneron.
  • J
    Jase
    This is the sleepiest $65 billion market cap stock that I have ever seen with cutting edge technology and products and high earnings growth. They are only averaging about 800,000 shares traded per day. The most effective therapy against the COVID pandemic ever available so far was just approved for use in the EU today, and very little volume or excitement of any kind for Regeneron.
  • J
    Justifiably Cynical.
  • J
    Jase
    The spike protein vaccines are declining in efficacy all over the world, and Europe in particular seems to be under a lot of pressure going into Winter. I would not be surprised if the USA follows with increasing infections and hospitalizations after Thanksgiving. It seems like this is a good investing climate for Regeneron given that their Regen-COV is the most effective therapy currently on the market and it also provides the longest lasting protection against the virus, especially with vulnerable patients who do not produce their own adequate antibody response.
    The analysts have been mostly predicting that Regen-COV would be declining in sales since Q2 2021, and that has simply not happened and will not happen anytime soon. The growing realization that Regen-COV will not be declining in sales in 2022 as much as had been expected could be the short term catalyst to re-value the stock at a higher level and to increase 2022 earnings estimates.
    My long-term bullish case in Regeneron is more based on their broad and deep pipeline, plus the potential of Dupixent to be a monster drug. Also, I am very optimistic about Regeneron's partnerships and drug development involving gene therapy. I ams till hoping that they will be able to buy NTLA at the right price for shareholders.
  • A
    Andrew
    The announcement yesterday regarding the U.S. Patent and Trademark Office's Patent Trial and Review Board planning to review two patents in the patent dispute between REGN and Mylan/Viatris, which is developing an Eylea biosimilar should not create any disturbance. Ophthalmologists have made Eylea the overwhelmingly preferred favorite among branded products for intravitreal use in macular degeneration and diabetic retinopathy and retinal vein occlusions. Eylea has a remarkable safety record and ophthalmologists will not switch to a biosimilar to save the system a few dollars.
  • I
    Ilya
    Co announced additional positive results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed use of a single dose of investigational REGEN-COV (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals. The new analyses show REGEN-COV reduced the risk of contracting COVID-19 (i.e., laboratory-confirmed symptomatic SARS-CoV-2 infections) by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction during the first month after administration, which was previously reported in The New England Journal of Medicine.
    In results previously published, the trial met its primary endpoint, reducing the risk of COVID-19 (i.e., laboratory-confirmed symptomatic SARS-CoV-2 infections) by 81.4% within 1 month of receiving REGEN-COV (p<0.0001). The new results released today describe a pre-specified analysis for the following 7 months, throughout which an additional 45 symptomatic infections occurred. During this time period, REGEN-COV continued to prevent infection, without requiring additional doses. Compared to placebo (n=842), people who received a single dose of REGEN-COV (n=841) experienced:
    81.6% reduced risk of developing COVID-19 during the pre-specified follow-up period, between months 2-8 (7 REGEN-COV, 38 placebo; 95% confidence interval [CI]: 59.8%, 91.6%; nominal p<0.0001).
    81.5% reduced risk of developing COVID-19 at any time during the 8 months after receiving REGEN-COV (20 REGEN-COV, 108 placebo; 95% CI: 70.6%,88.4%; nominal p<0.0001).
    During the 8-month assessment period, 0 individuals in the REGEN-COV group were hospitalized due to COVID-19, compared to 6 individuals in the placebo group (1 person in the first month; 5 people during months 2-8). There were no deaths due to COVID-19 in any treatment group during the 8-month assessment period, and there were no new safety signals identified for REGEN-COV.
    Regeneron is collaborating with Roche (RHHBY) to increase global supply of the antibody cocktail, with Roche primarily responsible for development and distribution outside the U.S. Regeneron and Roche share a commitment to making the antibody cocktail available to COVID-19 patients around the globe and will support access in low- and lower-middle-income countries through drug donations to be made in partnership with public health organizations.
  • J
    Juan
    The B11259 variant is being estimated as being 500% more competitively infectious than delta. The three infected in Israel had two shots and a booster. Good news is it doesn't look more lethal. Doesn't look trivial or a short passing news cycle.
  • A
    Andrew
    This drop is all about PFE and has nothing to do with the mixed shelf offering. Corporations often submit this type of a document at the time of quarterly reporting to provide for the future. A registration statement is a filing with the Securities and Exchange Commission to register a public offering, usually where there is no present intention to immediately sell all the securities being registered. A shelf registration statement permits multiple offerings based on the same registration. A shelf registration can be used for sales of new securities by the issuer or resales of outstanding securities or a combination of both.
    With a shelf registration statement, when the issuer wants to offer securities, it now can issue a prospectus and take them off the "shelf" and access capital markets quickly.
  • S
    Sams
    The Market just looks for reasons to sell off at this point.
  • J
    Jase
    OK, guys, it’s official. Regeneron and Roche will be able to sell all of the Regen-COV that they can make for the foreseeable future. I hope that they have a plan to immediately add production capacity.